Elizabeth Dudnik

1.9k total citations
69 papers, 1.2k citations indexed

About

Elizabeth Dudnik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Elizabeth Dudnik has authored 69 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Elizabeth Dudnik's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Elizabeth Dudnik is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Elizabeth Dudnik collaborates with scholars based in Israel, United States and Switzerland. Elizabeth Dudnik's co-authors include Nir Peled, Alona Zer, Tzippy Shochat, Ofer Rotem, Mira Wollner, Jair Bar, Mor Moskovitz, Hovav Nechushtan, Laila C. Roisman and Daniel A. Goldstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Elizabeth Dudnik

65 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth Dudnik Israel 19 817 717 221 185 155 69 1.2k
H. Kröning Germany 13 1.0k 1.3× 592 0.8× 179 0.8× 120 0.6× 199 1.3× 26 1.5k
Claudia Proto Italy 18 780 1.0× 531 0.7× 213 1.0× 150 0.8× 51 0.3× 93 1.2k
Mustapha Tehfé Canada 17 699 0.9× 656 0.9× 186 0.8× 145 0.8× 124 0.8× 90 1.1k
Thomas J. Semrad United States 15 395 0.5× 237 0.3× 257 1.2× 162 0.9× 99 0.6× 51 890
Anastasios Dimou United States 16 481 0.6× 311 0.4× 201 0.9× 115 0.6× 72 0.5× 67 800
Jane Liang United States 14 726 0.9× 629 0.9× 320 1.4× 84 0.5× 37 0.2× 23 1.2k
Motohiro Tamiya Japan 23 1.2k 1.5× 1.3k 1.8× 317 1.4× 189 1.0× 79 0.5× 163 1.9k
Roberto Moretto Italy 15 623 0.8× 207 0.3× 124 0.6× 144 0.8× 263 1.7× 69 872
Zhihuang Hu China 19 1.0k 1.2× 601 0.8× 514 2.3× 387 2.1× 123 0.8× 53 1.6k
Hazem El‐Osta United States 16 434 0.5× 234 0.3× 262 1.2× 109 0.6× 117 0.8× 35 893

Countries citing papers authored by Elizabeth Dudnik

Since Specialization
Citations

This map shows the geographic impact of Elizabeth Dudnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Dudnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Dudnik more than expected).

Fields of papers citing papers by Elizabeth Dudnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Dudnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Dudnik. The network helps show where Elizabeth Dudnik may publish in the future.

Co-authorship network of co-authors of Elizabeth Dudnik

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Dudnik. A scholar is included among the top collaborators of Elizabeth Dudnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Dudnik. Elizabeth Dudnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dudnik, Elizabeth, I. Lavi, Ofer Rotem, et al.. (2025). The impact of brain MRI screening on stage IV NSCLC patients: A real world look at guidelines based care. Journal of the Neurological Sciences. 470. 123398–123398.
2.
Tschernichovsky, Roi, Daniel A. Goldstein, Elizabeth Dudnik, et al.. (2023). Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature. Thoracic Cancer. 14(17). 1589–1596. 3 indexed citations
3.
Rotem, Ofer, Alona Zer, Einat Beery, et al.. (2023). Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy. Biomedicines. 11(6). 1730–1730. 3 indexed citations
4.
Leader, Avi, Erez Batat, Tzippy Shochat, et al.. (2023). Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. The Oncologist. 28(6). e391–e396. 4 indexed citations
5.
Moskovitz, Mor, Damien Urban, Hovav Nechushtan, et al.. (2021). dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer. 23(2). 122–134. 17 indexed citations
6.
Shimony, Shai, Tzippy Shochat, Galia Spectre, et al.. (2021). Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Haemostasis. 19(5). 1250–1258. 54 indexed citations
7.
Moore, Assaf, Shlomit Yust‐Katz, Noa Gordon, et al.. (2021). Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. Journal of the Neurological Sciences. 427. 117556–117556. 7 indexed citations
8.
Dudnik, Elizabeth, Abed Agbarya, Arnold Cyjon, et al.. (2020). Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. Clinical & Translational Oncology. 22(12). 2303–2311. 14 indexed citations
9.
Moore, Assaf, Mordechai R. Kramer, Dror Rosengarten, et al.. (2020). Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant. Radiology and Oncology. 54(2). 227–232. 1 indexed citations
10.
Rotem, Ofer, et al.. (2020). Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 143. 40–46. 37 indexed citations
11.
Refaely, Yael, et al.. (2020). Lung Cancer in Israel. Journal of Thoracic Oncology. 15(4). 493–498. 2 indexed citations
12.
Domachevsky, Liran, David Groshar, Elizabeth Dudnik, et al.. (2020). Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 17(2). e125–e131. 4 indexed citations
13.
Bar, Jair, Marina Perelman, Damien Urban, et al.. (2020). Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in Israel.. PubMed. 22(12). 788–793. 2 indexed citations
14.
Peled, Nir, et al.. (2019). Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.. PubMed. 21(6). 394–398. 1 indexed citations
15.
Dudnik, Elizabeth, Jair Bar, Mor Moskovitz, et al.. (2019). P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi. Journal of Thoracic Oncology. 14(10). S760–S760. 1 indexed citations
16.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations
17.
Wollner, Mira, Sivan Shamai, Nir Peled, et al.. (2019). Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. Journal of Immunotherapy. 43(2). 67–74. 14 indexed citations
18.
Peled, Nir, Moshe Mishaeli, Tzippy Shochat, et al.. (2019). Efficacy and Safety of <b><i>ALK</i></b> Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <b><i>ALK</i></b>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Oncology Research and Treatment. 42(5). 275–282. 8 indexed citations
19.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2017). OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology. 12(1). S326–S327. 1 indexed citations
20.
Dudnik, Elizabeth, Tali Siegal, Leor Zach, et al.. (2015). Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. Journal of Clinical Neuroscience. 26. 46–49. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Kröning Breakdown of academic impact, for papers by Claudia Proto Breakdown of academic impact, for papers by Mustapha Tehfé Breakdown of academic impact, for papers by Thomas J. Semrad Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Jane Liang Breakdown of academic impact, for papers by Motohiro Tamiya Breakdown of academic impact, for papers by Roberto Moretto Breakdown of academic impact, for papers by Zhihuang Hu Breakdown of academic impact, for papers by Hazem El‐Osta
Rankless by CCL
2026